In a revealing development, internal records have disclosed that senior officials from the Environmental Protection Agency (EPA) met with Bayer’s CEO, Bill Anderson, in June 2025 to discuss ongoing litigation surrounding the company’s glyphosate herbicide. This meeting has sparked alarm over the potential influence of corporate interests on regulatory decisions, particularly as the Trump administration has taken steps to bolster Bayer’s position in an upcoming Supreme Court case concerning allegations that its products cause cancer.
Meeting with EPA: A Turning Point for Bayer?
On 17 June 2025, officials from the EPA convened with Anderson and other Bayer executives to address “litigation” issues, which explicitly included discussions about “Supreme Court action” related to the glyphosate weed killer, Roundup. This meeting occurred amid mounting legal challenges, with thousands of individuals alleging that they developed cancer from using Bayer’s glyphosate-based products.
The focus of these lawsuits revolves around claims that Bayer neglected to inform consumers about the cancer risks associated with glyphosate. As the company grapples with billions of dollars in settlements and jury awards, Bayer has outlined its strategy to seek a ruling from the Supreme Court that could absolve it of liability if the EPA does not mandate a cancer warning on its glyphosate products.
Regulatory Backing from the Trump Administration
Following the June meeting, the Trump administration’s support for Bayer has become increasingly evident. Notably, the administration’s solicitor general, D John Sauer, submitted a filing on 1 December 2025 recommending that the Supreme Court take up Bayer’s case, a request that the court subsequently granted, scheduling a hearing for 27 April 2026.
Moreover, on 18 February 2026, the White House invoked the Defense Production Act to safeguard the production of glyphosate herbicides and effectively provide “immunity” to manufacturers like Bayer. Just weeks later, Sauer filed an amicus brief with the Supreme Court, representing the full backing of the U.S. government for Bayer’s position.
Concerns Over Corporate Influence
Critics have voiced concern regarding the implications of such high-level meetings between corporate leaders and government officials. Nathan Donley, the environmental health science director at the Center for Biological Diversity, remarked, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.” He highlighted the discrepancy in access to regulatory agencies, suggesting that ordinary citizens often lack the same opportunities for dialogue as industry representatives.
Legal experts have also expressed unease about the nature of the discussions held during the meeting. Whitney Di Bona, a consumer safety advocate, noted, “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability.” Such interactions raise questions about whether the EPA has similarly engaged with the thousands of individuals who claim to have suffered health consequences from glyphosate exposure.
Naomi Oreskes, a Harvard professor researching corporate influence in regulation, noted that the meeting exemplifies a troubling pattern where industry leaders have privileged access to government officials, while the voices of consumers remain unheard.
A Call for Accountability
Zen Honeycutt, founder of Moms Across America, highlighted the ongoing challenges that advocacy groups face when seeking regulatory action. “Coercion by chemical companies on our regulatory agencies is nothing new,” she stated. Despite multiple meetings with EPA leadership, her organisation has yet to see meaningful outcomes regarding calls to restrict or ban certain pesticides.
Bayer, in response to these concerns, described the meeting with the EPA as a “normal part of the regulatory process” and insisted that it has maintained transparency about its position concerning glyphosate litigation.
Why it Matters
The revelations surrounding the meeting between Bayer executives and EPA officials underscore a broader issue of corporate influence in regulatory spaces. As the Trump administration appears to align itself with Bayer’s interests, the implications for public health, consumer safety, and corporate accountability are profound. With the Supreme Court hearing on the horizon, the stakes are higher than ever, as thousands of individuals continue to seek justice for their alleged suffering due to glyphosate exposure. This situation calls for vigilance and advocacy to ensure that regulatory agencies prioritise public health over corporate profits.
